Publication: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
Issued Date
2021-12-01
Resource Type
ISSN
13494147
13488945
13488945
Other identifier(s)
2-s2.0-85107561397
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Tropical Medicine and Health. Vol.49, No.1 (2021)
Suggested Citation
Kay Thwe Han, Zay Yar Han, Kyin Hla Aye, Khin Thet Wai, Aung Thi, Liwang Cui, Jetsumon Sattabongkot G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination. Tropical Medicine and Health. Vol.49, No.1 (2021). doi:10.1186/s41182-021-00339-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77573
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination
Abstract
Background: Glucose 6-phosphate dehydrogenase deficiency (G6PDd) plays a central role in readiness assessment for malaria elimination in Myanmar by 2030 that includes primaquine (PQ) use. The risk of hemolysis in G6PDd individuals hampers the widespread use of primaquine safely in malaria-infected patients. In the pre-elimination era, it is important to screen initially for asymptomatic malaria in combination with G6PD deficiency by applying more sensitive diagnostic tools. Therefore, this study examined the proportion of G6PDd and the distribution of G6PD genotypes among malaria-infected national groups in Myanmar before initiation of malaria elimination strategies. Methods: A cross-sectional study in one township each with high malaria burden from two states in the western part of Myanmar, was conducted during 2016-2018, and 320 participants (164 Rakhine and 156 Chin National groups) were recruited. We used RDT and ultrasensitive polymerase chain reaction (us PCR) method to confirm malaria infection, and a G6PD RDT(CareStart) to detect G6PDd and PCR/restriction fragment length polymorphism (RFLP) method to confirm the variant of G6PDd for genotyping. G6PD enzyme activity was measured by G6PD Biosensor (CareStart). Results: Malaria positivity rates detected by RDT were lower than those detected by us PCR in the combined samples [13% (42/320) vs. 21% (67/320)] as well as in the Rakhine samples [17% (28/164) vs. 25% (41/164)] and in Chin samples [9% (14/156) vs. 17% (26/156)]. G6PD deficiency rates were approximately 10% in both the combined samples and specific national groups. For G6PD enzyme activity in the combined samples, G6PDd (defined as < 30% of adjusted male median) was 10% (31/320) and severe G6PDd (< 10% of AMM) was 3% (9/320). Among malaria-infected patients with positive by both RDT and usPCR, G6PDd was less than 20% in each national group. G6PD genotyping showed that the G6PD Mahidol (G487A) was the major variant. Conclusions: The varying degree of G6PDd detected among malaria-infected national groups by advanced diagnostic tools, strongly support the recommend G6PD testing by the National Malaria Control Program and the subsequent safe treatment of P. vivax by primaquine for radical cure. Establishing a field monitoring system to achieve timely malaria elimination is mandatory to observe the safety of patients after PQ treatment.
